Pelin Cinar

RT @ASCOPost Thank you for highlighting my journey - in appreciation of so many people who have mentored me through the years.

@AnaVManana @HemOncToday @UCSFCancer @ZSFGCare @Florez_Lab Fantastic news!!! Congratulations Ana- keep disrupting ❤️🤩

What an honor to be nominated for @HemOncToday NextGen Disruptor among so many amazing innovators, friends & people I admire! @UCSFCancer @ZSFGCare @Florez_Lab

@IshwariaMD @MDAndersonNews @BethGarciaMDA @JaniceSimon @VivekSubbiah @tricialeigh123 @TaniguchiMD @AraVaporciyan @ACKoongMDPhD So sorry to hear about your loss, Ishwaria! Sincere condolences.

An untimely death in my family meant I had to say my goodbyes to @MDAndersonNews a few days earlier than planned. Walked through the hallways that for 12 years served as my professional base camp. 📷,🎥of my last day. Always #endcancer! 🤜🤛🥂

@Dan_ChangMD @UMichRadOnc Congratulations Dan!!

Thank you @UMichRadOnc for being so welcoming and making me feel at home, especially in the house that Isadore, Allen, and Ted built! Looking forward to getting to work! First order of business: make the Michigan fan chain part of a new tradition! #GoBlue

Second interim analysis shows significant OS benefit! Trodelvy® Significantly Improves Overall Survival in Pre-Treated HR+/HER2- Metastatic Breast Cancer Patients in the TROPiCS-02 Study. ⁦@OncoAlert⁩ gilead.com/news-and-press…

@SwethaKMD @UCSFCancer @cityofhope Congratulations Swetha!! ❤️

Officially done with fellowship training! Excited to join the lymphoma division at COH as faculty. Incredibly grateful to all my mentors at @UCSFCancer and @cityofhope, colleagues, co-fellows, friends, and family for their support in this journey.Look forward to the next chapter!

I know I am at a medical conference - but in the last 3 hours, 3 speakers have used "patients have failed therapy" at least 7x. We don't fail treatment - the treatment may have failed, but patients are not failures - language matters.

Such a breath of fresh air to hear from a leadership that our wellness and work-life balance is a priority by setting and promoting working norms. Bravo @GileadOncology @GileadSciences! So proud to be a member of this culture.

Metastatic #TNBC is classified by what is absent from the tumor. But in today’s #MeanstoMe, See Phan discusses how new targets and continued research in this area has advanced treatment options. #ASCO22

This is what’s called disruptive science! Quoting Dr. @KimmieNgMD “Dr. @AndreaCercek & her team are trying to REPLACE EVERY component of standard of care…. ❌Neoadjuvant radiation ☢️ ❌Neoadjuvant chemo ❌Surgery (APR for some!)” 💯 complete response‼️ #ASCO22 @OncoAlert

@geoffreybuckle @DanaFarber @DanaFarber_GU @DrChoueiri Congratulations Geoff!! You’re awesome! 🎊🎉

In 2007, I began work as a clinical research coordinator @DanaFarber w/ no clinical experience, no medical knowledge, no marketable skills, and no obvious career path. I was extremely fortunate to join @DanaFarber_GU, and receive life-changing mentorship from @DrChoueiri

Incredible poster discussion on global oncology by Dr. Aparna Parikh (@aparna1024). She started by honoring Dr. Paul Farmer and his pioneering work in this field. Kudos to the authors! #ASCO22

It was an honor to present #ASCO22 with @Cpaller and @PCaParker about the role of #PSMAPET in biochemical recurrence. Can’t believe my first talk in Arie Crowne is @ASCO!

Almost everyone knows someone with breast cancer. That’s why Wendy Verret is motivated in her clinical research in HR+/HER2- metastatic breast cancer: She wants to help advance science for those living with or affected by the disease. Tune into her #MeanstoMe at #ASCO22.

Great session at #ASCO22 on ctDNA chaired by @pashtoonkasi. Some highlights include: Role of ctDNA guidance in stage 2 CRC presented by @jeannetie- reduced proportion of pts receiving adj chemo (28->15%) without compromise of 2-yr RFS (93.5 vs 92.4%).

@AnaVManana @UCSFCancer @ZSFGCare @NarjustDumaMD @LatinxOncology @Latinamd @RodriguezGIMD @NiharikaDixit16 @MattGubensMD @NCSP_UCSF @melisawongmd @KVanLoonMD @jillfeldman4 Fantastic news!!! Congratulations Ana- so happy and excited for you 🎉❤️

I guess it's time to let the cat out of the bag Excited to join @UCSFCancer @ZSFGCare Heme/Onc faculty this summer to fulfill my dreams of becoming a Thoracic Oncologist & work towards achieving equity in #LungCancer & #Latino health 🙏to family friends & mentors #ProductoUPR

This is the result of work, advocacy, and passion. Led by Dr. @MdBosserman and my amazing co-guest editors Drs. @GlopesMd @PelinCinarMD @miguelvillalon6 From workforce to clinical trial recruitment.

🚨 In our new pub @JCOOP_ASCO we discuss #latinx representation in the #oncology workforce A workforce that mirrors the diversity of our patients is critical to achieving *justice* in #healthcare & improving #Latino #health 👉 pubmed.ncbi.nlm.nih.gov/35544646/ #LatinosInOncology

So proud to have been involved in highlighting amazing work from colleagues on cancer disparities for Hispanic/Latinx patients in the US & offer potential approaches to increase equity @NarjustDumaMD @MdBosserman @miguelvillalon6 @GlopesMd #ASCOHealthEquity @JCOOP_ASCO @ASCO

@DevikaDasMD @HemOncWomenDocs @WIMChatSunday @HOJournalClub Congratulations Devika!! Wonderful news! 🎉🥳

For all clinicians on atypical career pathways,this for you! 🙏🏽 - non tenured - switched from private practice to academia - focus on QI in the VA Was unsure if I should even apply but this girl just got promoted to Clinical Associate Professor! 😭#womeninmedicine #Medtwitter

#GU22 @ASCO Abs#434 Oral presentation by @PGrivasMDPhD : Sacituzumab govitecan + Pembrolizumab in post platinum, IO naive metastatic #bladdercancer👉 encouraging ORR and disease control with no new safety signal👇 bit.ly/3HSusps @ONCOALERT @GileadSciences @urotoday